Theriva Biologics, Inc. (TOVX)
USD 1.04
(-0.95%)
USD 1.04
(-0.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -18.34 Million USD | 6.79% |
| 2022 | -19.68 Million USD | -38.88% |
| 2021 | -14.17 Million USD | -41.75% |
| 2020 | -9.99 Million USD | 33.43% |
| 2019 | -15.02 Million USD | -12.37% |
| 2018 | -13.36 Million USD | 11.91% |
| 2017 | -15.17 Million USD | 44.33% |
| 2016 | -27.25 Million USD | 37.68% |
| 2015 | -43.73 Million USD | -121.07% |
| 2014 | -19.78 Million USD | -60.62% |
| 2013 | -12.31 Million USD | 27.84% |
| 2012 | -17.06 Million USD | -109.45% |
| 2011 | -8.14 Million USD | -376.23% |
| 2010 | -1.71 Million USD | 54.14% |
| 2009 | -3.73 Million USD | 48.21% |
| 2008 | -7.2 Million USD | 27.16% |
| 2007 | -9.89 Million USD | -141.33% |
| 2006 | -4.09 Million USD | -202.33% |
| 2005 | -1.35 Million USD | 0.0% |
| 2002 | -8.61 Million USD | 9.09% |
| 2001 | -9.47 Million USD | -64.48% |
| 2000 | -5.76 Million USD | 66.85% |
| 1999 | -17.38 Million USD | 6.53% |
| 1998 | -18.6 Million USD | -95.79% |
| 1997 | -9.5 Million USD | -35.71% |
| 1996 | -7 Million USD | 5.41% |
| 1995 | -7.4 Million USD | -17.46% |
| 1994 | -6.3 Million USD | -61.54% |
| 1993 | -3.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.31 Million USD | -61.01% |
| 2024 Q1 | -5.16 Million USD | 5.83% |
| 2023 Q4 | -5.48 Million USD | -66.06% |
| 2023 Q3 | -3.3 Million USD | 35.03% |
| 2023 Q1 | -4.47 Million USD | 19.91% |
| 2023 Q2 | -5.08 Million USD | -13.53% |
| 2023 FY | -18.34 Million USD | 6.79% |
| 2022 Q4 | -5.59 Million USD | -18.93% |
| 2022 Q3 | -4.7 Million USD | 5.22% |
| 2022 Q2 | -4.96 Million USD | -14.89% |
| 2022 Q1 | -4.31 Million USD | 17.97% |
| 2022 FY | -19.68 Million USD | -38.88% |
| 2021 Q4 | -5.26 Million USD | -60.8% |
| 2021 FY | -14.17 Million USD | -41.75% |
| 2021 Q1 | -2.53 Million USD | -20.25% |
| 2021 Q2 | -3.19 Million USD | -25.99% |
| 2021 Q3 | -3.27 Million USD | -2.44% |
| 2020 FY | -9.99 Million USD | 33.43% |
| 2020 Q1 | -2.96 Million USD | 5.61% |
| 2020 Q2 | -2.86 Million USD | 3.27% |
| 2020 Q3 | -2.1 Million USD | 26.65% |
| 2020 Q4 | -2.1 Million USD | -0.29% |
| 2019 Q2 | -3.53 Million USD | -0.54% |
| 2019 Q4 | -3.14 Million USD | 38.67% |
| 2019 Q3 | -5.12 Million USD | -45.0% |
| 2019 FY | -15.02 Million USD | -12.37% |
| 2019 Q1 | -3.51 Million USD | -10.68% |
| 2018 Q2 | -4.19 Million USD | -81.22% |
| 2018 Q1 | -2.31 Million USD | -181.26% |
| 2018 Q3 | -3.68 Million USD | 12.32% |
| 2018 FY | -13.36 Million USD | 11.91% |
| 2018 Q4 | -3.17 Million USD | 13.78% |
| 2017 Q3 | -10.92 Million USD | -156.69% |
| 2017 Q1 | -2.84 Million USD | -19.83% |
| 2017 Q4 | 2.85 Million USD | 126.09% |
| 2017 FY | -15.17 Million USD | 44.33% |
| 2017 Q2 | -4.25 Million USD | -49.51% |
| 2016 Q4 | -2.37 Million USD | 71.57% |
| 2016 Q1 | -10.84 Million USD | 1.25% |
| 2016 Q2 | -5.68 Million USD | 47.61% |
| 2016 Q3 | -8.35 Million USD | -47.01% |
| 2016 FY | -27.25 Million USD | 37.68% |
| 2015 Q3 | -6.77 Million USD | 50.28% |
| 2015 Q2 | -13.62 Million USD | -10.24% |
| 2015 Q1 | -12.35 Million USD | -90.71% |
| 2015 FY | -43.73 Million USD | -121.07% |
| 2015 Q4 | -10.98 Million USD | -62.12% |
| 2014 Q2 | -4.55 Million USD | -18.71% |
| 2014 Q1 | -3.83 Million USD | 9.14% |
| 2014 Q4 | -6.48 Million USD | -31.98% |
| 2014 FY | -19.78 Million USD | -60.62% |
| 2014 Q3 | -4.91 Million USD | -7.77% |
| 2013 FY | -12.31 Million USD | 27.84% |
| 2013 Q3 | -3.36 Million USD | -34.88% |
| 2013 Q4 | -4.22 Million USD | -25.42% |
| 2013 Q1 | -2.22 Million USD | 81.53% |
| 2013 Q2 | -2.49 Million USD | -12.07% |
| 2012 Q3 | -1.93 Million USD | -3.1% |
| 2012 Q4 | -12.06 Million USD | -525.18% |
| 2012 FY | -17.06 Million USD | -109.45% |
| 2012 Q2 | -1.87 Million USD | -56.0% |
| 2012 Q1 | -1.2 Million USD | 62.32% |
| 2011 Q1 | -2.18 Million USD | -151.15% |
| 2011 Q2 | -1.67 Million USD | 23.17% |
| 2011 Q3 | -1.09 Million USD | 34.64% |
| 2011 Q4 | -3.18 Million USD | -190.05% |
| 2011 FY | -8.14 Million USD | -376.23% |
| 2010 Q1 | -1.08 Million USD | 2.36% |
| 2010 FY | -1.71 Million USD | 54.14% |
| 2010 Q2 | 979.78 Thousand USD | 190.09% |
| 2010 Q4 | -870.58 Thousand USD | -18.8% |
| 2010 Q3 | -732.83 Thousand USD | -174.8% |
| 2009 Q3 | -626.07 Thousand USD | 28.82% |
| 2009 FY | -3.73 Million USD | 48.21% |
| 2009 Q2 | -879.55 Thousand USD | 20.99% |
| 2009 Q1 | -1.11 Million USD | -21.65% |
| 2009 Q4 | -1.11 Million USD | -77.9% |
| 2008 FY | -7.2 Million USD | 27.16% |
| 2008 Q2 | -1.77 Million USD | 42.65% |
| 2008 Q4 | -915.15 Thousand USD | 35.95% |
| 2008 Q3 | -1.42 Million USD | 19.35% |
| 2008 Q1 | -3.08 Million USD | 2.22% |
| 2007 Q3 | -2.12 Million USD | -20.34% |
| 2007 Q1 | -2.84 Million USD | 30.36% |
| 2007 Q2 | -1.76 Million USD | 38.15% |
| 2007 FY | -9.89 Million USD | -141.33% |
| 2007 Q4 | -3.15 Million USD | -48.97% |
| 2006 Q1 | -515.53 Thousand USD | 0.0% |
| 2006 Q2 | -4363.00 USD | 99.15% |
| 2006 Q3 | -3017.00 USD | 30.85% |
| 2006 FY | -4.09 Million USD | -202.33% |
| 2006 Q4 | -4.09 Million USD | -135521.98% |
| 2005 FY | -1.35 Million USD | 0.0% |
| 2003 Q1 | -880.86 Thousand USD | 12.3% |
| 2002 Q3 | -1.3 Million USD | 58.99% |
| 2002 FY | -8.61 Million USD | 9.09% |
| 2002 Q1 | -3.13 Million USD | -3.54% |
| 2002 Q2 | -3.17 Million USD | -1.38% |
| 2002 Q4 | -1 Million USD | 22.9% |
| 2001 Q3 | -2.59 Million USD | -13.75% |
| 2001 Q2 | -2.27 Million USD | -44.23% |
| 2001 Q1 | -1.58 Million USD | 1.48% |
| 2001 FY | -9.47 Million USD | -64.48% |
| 2001 Q4 | -3.02 Million USD | -16.73% |
| 2000 Q1 | -1.45 Million USD | 89.03% |
| 2000 Q4 | -1.6 Million USD | -21.69% |
| 2000 Q3 | -1.31 Million USD | 4.75% |
| 2000 Q2 | -1.38 Million USD | 5.03% |
| 2000 FY | -5.76 Million USD | 66.85% |
| 1999 Q2 | -1.5 Million USD | -25.0% |
| 1999 FY | -17.38 Million USD | 6.53% |
| 1999 Q1 | -1.2 Million USD | -33.33% |
| 1999 Q4 | -13.28 Million USD | -785.65% |
| 1999 Q3 | -1.5 Million USD | 0.0% |
| 1998 Q3 | -2.1 Million USD | 84.21% |
| 1998 Q4 | -900 Thousand USD | 57.14% |
| 1998 FY | -18.6 Million USD | -95.79% |
| 1998 Q2 | -13.3 Million USD | -478.26% |
| 1998 Q1 | -2.3 Million USD | -53.33% |
| 1997 Q4 | -1.5 Million USD | 21.05% |
| 1997 Q2 | -3.4 Million USD | -25.93% |
| 1997 Q1 | -2.7 Million USD | -28.57% |
| 1997 FY | -9.5 Million USD | -35.71% |
| 1997 Q3 | -1.9 Million USD | 44.12% |
| 1996 Q1 | -1.7 Million USD | 15.0% |
| 1996 Q2 | -1.7 Million USD | 0.0% |
| 1996 Q4 | -2.1 Million USD | -31.25% |
| 1996 Q3 | -1.6 Million USD | 5.88% |
| 1996 FY | -7 Million USD | 5.41% |
| 1995 Q4 | -2 Million USD | 4.76% |
| 1995 Q1 | -1.4 Million USD | 12.5% |
| 1995 FY | -7.4 Million USD | -17.46% |
| 1995 Q2 | -1.9 Million USD | -35.71% |
| 1995 Q3 | -2.1 Million USD | -10.53% |
| 1994 Q2 | -1.6 Million USD | -300.0% |
| 1994 Q1 | -400 Thousand USD | 73.33% |
| 1994 Q3 | -1.6 Million USD | 0.0% |
| 1994 FY | -6.3 Million USD | -61.54% |
| 1994 Q4 | -1.6 Million USD | 0.0% |
| 1993 Q3 | -1.4 Million USD | -180.0% |
| 1993 FY | -3.9 Million USD | 0.0% |
| 1993 Q1 | -500 Thousand USD | 0.0% |
| 1993 Q4 | -1.5 Million USD | -7.14% |
| 1993 Q2 | -500 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 36.645% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -112.57% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 73.425% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 62.413% |
| Azitra, Inc. | -11.28 Million USD | -62.614% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -140.359% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -148.605% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 37.195% |
| CEL-SCI Corporation | -32.36 Million USD | 43.308% |
| iBio, Inc. | -24.9 Million USD | 26.33% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 14.6% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 7.201% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 20.02% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -20.899% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -90.342% |
| NanoViricides, Inc. | -8.29 Million USD | -121.228% |
| Oragenics, Inc. | -20.65 Million USD | 11.168% |
| BiomX Inc. | -26.16 Million USD | 29.883% |
| BiomX Inc. | -26.16 Million USD | 29.883% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 320.753% |
| Palatin Technologies, Inc. | -29.73 Million USD | 38.294% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 59.42% |